MiR-4721, Induced by EBV-miR-BART22, Targets to Enhance the Tumorigenic Capacity of NPC Through the Pathway
Overview
Authors
Affiliations
Nasopharyngeal carcinoma (NPC) is prevalent in East and Southeast Asia. In a previous study, Epstein-Barr virus (EBV)-miR-BART22 induces tumor metastasis and stemness and is significantly involved in NPC progression. In the present study, we observed that miR-4721 is induced by EBV-miR-BART22 through phosphatidylinositol 3-kinase (PI3K)/AKT/c-JUN/Sp1 signaling to promote its transcription. In a subsequent study, we observed that miR-4721 serves as a potential oncogenic factor promoting NPC cell cycle progression and cell proliferation and . Mechanism analysis indicated that miR-4721 directly targetes GSK3β and reduces its expression, which therefore elevates β-catenin intra-nuclear aggregation and activates its downstream cell cycle factors, including CCND1 and c-MYC. In clinical samples, miR-4721 and GSK3β are respectively observed to be upregulated and downregulated in NPC progression. Elevated expression of miR-4721 is positively associated with clinical progression and poor prognosis. Our study first demonstrated that miR-4721 as an oncogene is induced by EBV-miR-BART22 via modulating PI3K/AKT/c-JUN/Sp1 signaling to target GSK3β, which thus activates the WNT/β-catenin-stimulated cell cycle signal and enhances the tumorigenic capacity in NPC. miR-4721 may be a potential biomarker or therapeutic target in NPC treatment in the future.
Zhao M, Zhang N, Wang Y, Han K, Gao T, Li X J Cancer. 2024; 15(18):5863-5875.
PMID: 39440051 PMC: 11493013. DOI: 10.7150/jca.100210.
Unique lipid composition maintained by extracellular blockade leads to prooncogenicity.
Kudo K, Yanagiya R, Hasegawa M, Carreras J, Miki Y, Nakayama S Cell Death Discov. 2024; 10(1):221.
PMID: 38719806 PMC: 11079073. DOI: 10.1038/s41420-024-01971-y.
Xu Y, Chen Y, Yang Q, Lu Y, Zhou R, Liu H Heliyon. 2024; 10(5):e26810.
PMID: 38444478 PMC: 10912469. DOI: 10.1016/j.heliyon.2024.e26810.
Kashyap D, Rele S, Bagde P, Saini V, Chatterjee D, Jain A Arch Microbiol. 2023; 205(7):262.
PMID: 37310490 DOI: 10.1007/s00203-023-03598-6.
Huang X, Yu Q Front Endocrinol (Lausanne). 2023; 14:1137235.
PMID: 37008951 PMC: 10050890. DOI: 10.3389/fendo.2023.1137235.